Serina Therapeutics, Inc. 8-K

What Happened

• On May 14, 2026, Serina Therapeutics, Inc. (SER) filed a Form 8-K (Item 2.02) to announce its financial results for the quarter ended March 31, 2026. The company furnished a press release as Exhibit 99.1 to the filing. The 8-K was signed by CEO Steve Ledger.

Key Details

• Filing date: May 14, 2026 (Form 8-K, Item 2.02).
• Reporting period: quarter ended March 31, 2026.
• Press release furnished as Exhibit 99.1 to the 8-K.
• Form 8-K was signed by Chief Executive Officer Steve Ledger.

Why It Matters

• The company officially communicated its quarterly financial performance to investors and the market; the press release will contain the key numbers (revenue, expenses, cash position, and any commentary or guidance).
• Retail investors should read the Exhibit 99.1 press release for the actual financial figures and management commentary, and compare those results to prior quarters and company guidance to assess near-term outlook. The 8-K does not report any other material events (e.g., executive departures or transactions) beyond the earnings release.